International Journal of Antimicrobial Agents
Volume 35, Issue 4 , Pages 357-361 , April 2010

The designer proline-rich antibacterial peptide A3-APO is effective against systemic Escherichia coli infections in different mouse models

  • Dora Szabo

      Affiliations

    • Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary
    • These authors contributed equally to this study.
    • ,
  • Eszter Ostorhazi

      Affiliations

    • Microbiology Laboratory, Department of Dermatology, Venereology and Dermato-oncology, Semmelweis University, Budapest, Hungary
    • These authors contributed equally to this study.
    • ,
  • Annegret Binas

      Affiliations

    • AiCuris GmbH & Co. KG, Wuppertal, Germany
    • ,
  • Ferenc Rozgonyi

      Affiliations

    • Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary
    • Microbiology Laboratory, Department of Dermatology, Venereology and Dermato-oncology, Semmelweis University, Budapest, Hungary
    • ,
  • Bela Kocsis

      Affiliations

    • Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary
    • ,
  • Marco Cassone

      Affiliations

    • Sbarro Institute for Cancer Research and Molecular Medicine, Temple University, Philadelphia, PA 19122, USA
    • ,
  • John D. Wade

      Affiliations

    • Howard Florey Institute, University of Melbourne, Victoria 3010, Australia
    • School of Chemistry, University of Melbourne, Victoria 3010, Australia
    • ,
  • Oliver Nolte

      Affiliations

    • AiCuris GmbH & Co. KG, Wuppertal, Germany
    • ,
  • Laszlo Otvos Jr

      Affiliations

    • Department of Biology, Temple University, Philadelphia, PA 19122, USA
    • Corresponding Author InformationCorresponding author. Present address: Temple University, BioLife Sciences Building, 1900 North 12th Street, Philadelphia, PA 19122, USA. Tel.: +1 215 204 4020; fax: +1 215 204 6646.

Received 2 September 2009 ,Accepted 19 October 2009.

References 

  1. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature. 2002;415:389–395
  2. Ge Y, MacDonald DL, Holroyd KJ, Thornsberry C, Wexler H, Zasloff M. In vitro properties of pexiganan, an analog of magainin. Antimicrob Agents Chemother. 1999;43:782–788
  3. Bush K, Macielag M, Weidner-Wells M. Taking inventory: antibacterial agents currently at or beyond Phase I. Curr Opin Microbiol. 2004;7:466–476
  4. Marr AK, Gooderham WJ, Hancock REW. Antibacterial peptides for therapeutic use: obstacles and realistic outlook. Curr Opin Pharmacol. 2006;6:468–472
  5. Dartois V, Sanchez-Quesada J, Cabezas E, Chi E, Dubbelde C, Dunn C, et al. Systemic antibacterial activity of novel synthetic cyclic peptides. Antimicrob Agents Chemother. 2005;49:3302–3310
  6. Deslouches B, Islam K, Craigo JK, Paranjape SM, Montelaro RC, Mietzner TA. Activity of the de novo engineered antimicrobial peptide WLBU2 against Pseudomonas aeruginosa in human serum and whole blood: implications for systemic applications. Antimicrob Agents Chemother. 2005;49:3208–3216
  7. Otvos L, Wade JD, Lin F, Condie BA, Hanrieder J, Hoffmann R. Designer antibacterial peptides kill fluoroquinolone-resistant clinical isolates. J Med Chem. 2005;48:5349–5359
  8. Otvos L, Snyder C, Condie B, Bulet P, Wade JD. Chimeric antimicrobial peptides exhibit multiple modes of action. Int J Pept Res Ther. 2005;11:29–42
  9. Otvos L, de Olivier Inacio V, Wade JD, Cudic P. Prior antibacterial peptide-mediated inhibition of protein folding in bacteria mutes resistance enzymes. Antimicrob Agents Chemother. 2006;50:3146–3149
  10. Kragol G, Lovas S, Varadi G, Condie BA, Hoffmann R, Otvos L. The antibacterial peptide pyrrhocoricin inhibits the ATPase actions of DnaK and prevents chaperone-assisted protein folding. Biochemistry. 2001;40:3016–3026
  11. Noto PB, Abbadessa G, Cassone M, Mateo GD, Agelan A, Wade JD, et al. Alternative stabilities of a proline-rich antibacterial peptide in vitro and in vivo. Protein Sci. 2008;17:1249–1255
  12. Kim JM, Ha JR, Oh SW, Kim HG, Lee JM, Lee DG, et al. CW-270033, a novel pyrrolidinyl-thio carbapenem, has potent antimicrobial activity in vitro and in vivo. Biol Pharm Bull. 2007;30:575–579
  13. Klootwijk W, Sleddens-Linkels E, de Boer R, Jansen CA, Autar R, de Herder WW, et al. Renal clearance of the thyrotropin-releasing hormone-like peptide pyroglutamyl-glutamyl-prolineamide in humans. J Clin Endocrinol Metab. 1997;82:3068–3073
  14. Sakamoto H, Hatano K, HigashiY , Mine Y, Nakamoto S, Tawara S, et al. Animal pharmacokinetics of FK037, a novel parenteral broad-spectrum cephalosporin. J Antibiot (Tokyo). 1993;46:120–130
  15. Fields GB, Noble RL. Solid-phase peptide synthesis using 9-fluorenylmethoxycarbonyl amino acids. Int J Pept Protein Res. 1990;35:161–214
  16. Amsterdam D. Susceptibility testing of antimicrobials in liquid media. In:  Loman V editors. Antibiotics in laboratory medicine. Philadelphia, PA: Williams and Wilkins; 1996;p. 52–111
  17. Otvos L, O I, Rogers ME, Consolvo PJ, Condie BA, Lovas S, et al. Interaction between heat shock proteins and antimicrobial peptides. Biochemistry. 2000;39:14150–14159
  18. Kragol G, Hoffmann R, Chattergoon MA, Lovas S, Cudic M, Bulet P, et al. Identification of crucial residues for the antibacterial activity of the proline-rich peptide, pyrrhocoricin. Eur J Biochem. 2002;269:4226–4237
  19. Cassone M, Vogiatzi P, La Montagna R, De Olivier Inacio V, Cudic P, Wade JD, et al. Scope and limitations of the designer proline-rich antibacterial peptide dimer, A3-APO, alone or in synergy with conventional antibiotics. Peptides. 2008;29:1878–1886
  20. Otvos L. Antibacterial peptides and proteins with multiple cellular targets. J Pept Sci. 2005;11:697–706
  21. Cassone M, Frith N, Vogiatzi P, Wade JD, Otvos L. Induced resistance to the designer proline-rich antimicrobial peptide A3-APO does not involve changes in the intracellular target DnaK. Int J Pept Res Ther. 2009;15:121–128
  22. Rozgonyi F, Szabo D, Kocsis B, Ostorházi E, Abbadessa G, Cassone M, et al. The antibacterial effect of a proline-rich antibacterial peptide A3-APO. Curr Med Chem. 2009;16:3996–4002
  23. Fumarola D, Marcuccio L, Fransvea P, Pasquetto N, Miragliotta G, Brienza A. Attempted protection against experimental endotoxic shock. G Batteriol Virol Immunol. 1975;68:224–230[in Italian]
  24. Byl BP, Clevenbergh A, Kentos F, Jacobs F, Marchant A, Vincent JL, et al. Ceftazidime- and imipenem-induced endotoxin release during treatment of Gram-negative infections. Eur J Clin Microbiol Infect Dis. 2001;20:804–807
  25. Máthé A, Komka K, Forczig M, Szabó D, Anderlik P, Rozgonyi F. The effect of different doses of cisplatin on the pharmacokinetic parameters of cefepime in mice. Lab Anim. 2006;40:296–300
  26. Edwards JR, Williams S, Nairn K. Therapeutic activity of meropenem in experimental infections. J Antimicrob Chemother. 1989;24(Suppl. A):279–285
  27. Cudic M, Lockatell CV, Johnson DE, Otvos L. In vitro and in vivo activity of a designed antibacterial peptide analog against uropathogens. Peptides. 2003;24:807–820

PII: S0924-8579(09)00490-7

doi: 10.1016/j.ijantimicag.2009.10.015

International Journal of Antimicrobial Agents
Volume 35, Issue 4 , Pages 357-361 , April 2010

Article Tools

* Image Usage & Resolution